MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.92
+0.38
+2.45%
After Hours: 15.92 0 0.00% 16:47 01/24 EST
OPEN
15.25
PREV CLOSE
15.54
HIGH
16.12
LOW
14.38
VOLUME
642.22K
TURNOVER
--
52 WEEK HIGH
43.32
52 WEEK LOW
14.38
MARKET CAP
1.29B
P/E (TTM)
-35.7672
1D
5D
1M
3M
1Y
5Y
International Petroleum Corporation to Arrange Fixed Income Investor Meetings
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- International Petroleum Corporation ("IPC" or the "Corporation") (TSX, Nasdaq Stockholm: IPCO) announces that it is planning to arrange fixed income investor meetings in connection with a potential issuance of rat...
GlobeNewswire · 01/11 06:30
International Petroleum Corporation Announces Corporate Credit Ratings
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- International Petroleum Corporation ("IPC" or the "Corporation") (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that international credit rating agencies Moody’s and S&P Global Ratings have assigned corporat...
GlobeNewswire · 01/11 06:30
Why Shehnaaz Suliman threw in with a young biotech for her first CEO gig
The emails started flooding Dr. Shehnaaz Suliman's inbox as soon as word got out this fall that she would be leaving her job as president and COO at Alector Inc. One message stood out: a small Menlo Park biotech company hoping to launch clinical trials in...
American City Business Journals · 01/10 16:07
Marin Software, Duck Creek Technologies lead aftermarket gainers; Dogness, Alector among losers
Gainers: Marin Software MRIN +37%, Duck Creek Technologies DCT +7%, Bed Bath & Beyond BBBY +7%, Moderna (NASDAQ:MRNA) +6%, QuinStreet (NASDAQ:QNST) +5%. Losers: Dogness (NASDAQ:DOGZ) -6%, Alector (NASDAQ:ALEC) -5%, Annexon (NASDAQ:ANNX) -5%, Adicet Bio (NA...
Seekingalpha · 01/06 22:29
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Sara Ke...
GlobeNewswire · 01/03 21:30
Alector, Inc. (NASDAQ:ALEC) Has Found A Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Alector, Inc.'s...
Simply Wall St. · 01/02 11:32
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Phar...
GuruFocus.com · 12/24/2021 05:38
Peninsula brain drug company snags Genentech vet as president
Sara Kenkare-Mitra received a $500,000 sign-on bonus as the company pushes its Alzheimer's and frontotemporal dementia drugs deeper into clinical trials.
American City Business Journals · 12/16/2021 16:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

55.56%Strong Buy
44.44%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALEC stock price target is 45.14 with a high estimate of 57.00 and a low estimate of 32.00.
High57.00
Average45.14
Low32.00
Current 15.92
EPS
Actual
Estimate
-0.030.631.291.95
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 190
Institutional Holdings: 57.28M
% Owned: 70.48%
Shares Outstanding: 81.28M
TypeInstitutionsShares
Increased
59
4.75M
New
22
2.46M
Decreased
25
2.26M
Sold Out
14
1.77M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President
Saraswati Kenkare-mitra
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Chief Financial Officer/Chief Accounting Officer
Linda Rubinstein
Vice President - Finance
Calvin Yu
Other
Sam Jackson
Other
Robert King
Lead Director/Independent Director
Louis Lavigne
Director
Elizabeth Garofalo
Independent Director
Paula Hammond
Independent Director
Terry Mcguire
Independent Director
Richard Scheller
Independent Director
David Wehner
Independent Director
Kristine Yaffe
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL002, AL003, and AL101. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.